初治套细胞淋巴瘤患者的治疗结局及移植与利妥昔单抗维持治疗的作用:来自大型真实世界队列的结果
该回顾性研究分析了2011至2021年诊断的4216例套细胞淋巴瘤患者的治疗模式和结局,主要来自美国社区肿瘤实践,并在12个学术中心的1168例独立队列中验证。在适合ASCT的患者中,ASCT与至下一次治疗时间或总生存无显著关联;在适合MR的患者中,BR后MR较单用BR与更长的至下一次治疗时间和总生存相关。
要点
- 在适合ASCT的患者中,ASCT与至下一次治疗时间(HR 0.84;95%CI 0.68-1.03;P=.10)或总生存(HR 0.86;95%CI 0.63-1.18;P=.4)无显著关联。
- 在适合MR的患者中,BR后MR较单用BR与更长的至下一次治疗时间(HR 1.96;95%CI 1.61-2.38;P<.001)和总生存(HR 1.51;95%CI 1.19-1.92;P<.001)相关。
- 在1265例年龄<65岁患者中,30.5%接受含阿糖胞苷诱导,23.5%接受ASCT。
核心结论
- 在这个主要在美国社区医疗环境下治疗的大型队列中,仅四分之一的年轻患者接受了阿糖胞苷或ASCT巩固治疗,提示需要开发可在常规临床实践中有效实施的疗法。
- 结合验证队列,数据支持未来在年轻患者中探索不含ASCT巩固的方案,而BR和R-CHOP一线治疗后应考虑MR。
研究设计与样本
- 回顾性研究,评估2011年至2021年诊断的4216例套细胞淋巴瘤患者的治疗模式和结局,数据来自Flatiron Health电子记录衍生去标识数据库,主要来自美国社区肿瘤实践。
- ASCT和MR的疗效发现在来自12个学术中心的1168例独立队列中验证。
主要发现
- 在3614例有 documented 一线治疗的患者中,BR是最常用的方案。
- 在1265例年龄<65岁患者中,30.5%接受含阿糖胞苷诱导,23.5%接受ASCT。
- 在适合ASCT的患者中,ASCT与至下一次治疗时间(HR 0.84;95%CI 0.68-1.03;P=.10)或总生存(HR 0.86;95%CI 0.63-1.18;P=.4)无显著关联。
- 在适合MR的患者中,BR后MR较单用BR与更长的至下一次治疗时间(HR 1.96;95%CI 1.61-2.38;P<.001)和总生存(HR 1.51;95%CI 1.19-1.92;P<.001)相关。
- 疗效发现在验证队列中一致。
临床怎么用
- 作者认为,BR和R-CHOP一线治疗后应考虑MR。
- 作者认为,数据支持未来在年轻患者中探索不含ASCT巩固的方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Commonly used first-line (1L) treatments for mantle cell lymphoma include high-dose cytarabine-based induction followed by autologous stem-cell transplant (ASCT) for younger patients and several chemoimmunotherapy regimens for older patients. Continuous debates exist on the role of ASCT in younger patients and maintenance rituximab (MR) after bendamustine plus rituximab (BR). METHODS: Retrospective data from 4,216 patients with mantle cell lymphoma in the Flatiron Health electronic record-derived deidentified database diagnosed between 2011 and 2021, mostly in US community oncology settings, were evaluated for treatment patterns and outcomes. The efficacy findings with ASCT and MR were validated in an independent cohort of 1,168 patients from 12 academic centers. RESULTS: Among 3,614 patients with documented 1L treatment, BR was the most used. Among 1,265 patients age < 65 years, 30.5% received cytarabine-based induction and 23.5% received ASCT. There was no significant association between ASCT and real-world time to next treatment (hazard ratio [HR], 0.84; 95% CI, 0.68 to 1.03; P = .10) or overall survival (HR, 0.86; 95% CI, 0.63 to 1.18; P = .4) among ASCT-eligible patients. Among MR-eligible patients, MR after BR versus BR alone was associated with a longer real-world time to next treatment (HR, 1.96; 95% CI, 1.61 to 2.38; P < .001) and overall survival (HR, 1.51; 95% CI, 1.19 to 1.92; P < .001). The efficacy findings were consistent in the validation cohort. CONCLUSION: In this large cohort of patients treated primarily in the US community setting, only one in four young patients received cytarabine or ASCT consolidation, suggesting the need to develop treatments that can be delivered effectively in routine clinical practice. Together with the validation cohort, data support future clinical trials exploring regimens without ASCT consolidation in young patients, whereas MR should be considered for patients after 1L BR and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
引用
- Martin P, Cohen JB, Wang M, et al. Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts. J Clin Oncol. 2022. PMID: 35763708. doi:10.1200/JCO.21.02698
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。